Pyrimidines

On October 26, 2020, Curti, Claudio; Rassu, Gloria; Lombardo, Marco; Zambrano, Vincenzo; Pinna, Luigi; Battistini, Lucia; Sartori, Andrea; Pelosi, Giorgio; Zanardi, Franca published an article.Application of 626-48-2 The title of the article was Unlocking Access to Enantiopure Fused Uracils by Chemodivergent [4+2] Cross-Cycloadditions: DFT-Supported Homo-Synergistic Organocatalytic Approach. And the article contained the following:

The discovery of chem. methods enabling the construction of carbocycle-fused uracils which embody a three-dimensional and functional-group-rich architecture is a useful tool in medicinal chem. oriented synthesis. In this work, an unprecedented amine-catalyzed [4+2] cross-cycloaddition is documented; it involves remotely enolizable 6-methyluracil-5-carbaldehydes and β-aryl enals, and chemoselectively produces two novel bicyclic and tricyclic fused uracil chemotypes in good yields with a maximum level of enantiocontrol. In-depth mechanistic investigations and control experiments support an intriguing homo-synergistic organocatalytic approach, where the same amine organocatalyst concomitantly engages both aldehyde partners in a stepwise eliminative [4+2] cycloaddition, whose vinylogous iminium ion intermediate product may diverge-depending upon conditions-to either bicyclic targets by hydrolysis or tricyclic products by a second homo-synergistic trienamine-mediated stepwise [4+2] cycloaddition The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Application of 626-48-2

The Article related to uracil cinnamaldehyde chemoselective regioselective diastereoselective enantioselective organocatalysis cycloaddition, carbocycle fused uracil stereoselective preparation, asymmetric synthesis, cycloaddition, fused-ring systems, heterocycles, organocatalysis and other aspects.Application of 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Jakubiec, Dominika; Przypis, Lukasz; Suwinski, Jerzy W.; Walczak, Krzysztof Z. published an article in 2017, the title of the article was Synthesis of 5-hetaryluracil derivatives via 1,3-dipolar cycloaddition reaction.Synthetic Route of 4433-40-3 And the article contains the following content:

1,3-Dipolar cycloaddition was applied for the synthesis 5-hetaryluracil derivatives where substituted uracils played the role of 1,3-dipoles or dipolarophiles. Treatment of the nitrile oxide derived from 5-formyluracil and substituted alkenes gave the appropriate 5-(4,5-dihydroisoxazol-3-yl)pyrimidine-2,4(1H,3H)-diones, which by oxidation with N-bromosuccinimide were transformed into appropriate 5-(isoxazol-3-yl)uracils. When 5-cyanouracil was used as a dipolarophile in the reaction with nitrile oxides, generated from aromatic aldoximes, several 5-(1,2,4-oxadiazol-5-yl)uracils were obtained. An alternative reaction of 5-formyluracil with an excess of nitriles in the presence of cerium ammonium nitrate as an oxidant gave 1,2,4-oxadiazol-3-yl derivatives in moderate yields. The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Synthetic Route of 4433-40-3

The Article related to dioxopyrimidinyl aldoxime preparation alkene regioselective dipolar cycloaddition, dihydroisoxazolyl uracil preparation, nitrile dioxopyrimidinyl aldoxime dipolar cycloaddition, oxadiazoyl uracil preparation, phenyl aldoxime cyanouracil dipolar cycloaddition and other aspects.Synthetic Route of 4433-40-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 1, 2017, Woodring, Jennifer L.; Bachovchin, Kelly A.; Brady, Kimberly G.; Gallerstein, Mitchell F.; Erath, Jessey; Tanghe, Scott; Leed, Susan E.; Rodriguez, Ana; Mensa-Wilmot, Kojo; Sciotti, Richard J.; Pollastri, Michael P. published an article.COA of Formula: C8H10BrN3O The title of the article was Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation. And the article contained the following:

Human African trypanosomiasis (HAT) is a deadly disease in need of new chemotherapeutics that can cross into the central nervous system. The authors previously reported the discovery of (NEU-617), a small mol. with activity against T. brucei bloodstream proliferation. Further optimization of NEU-617 to improve the physicochem. properties (LogP, LLE, [1], and MPO score) [2] have led us to twelve sub-micromolar compounds, most importantly the headgroup variants I and II, and the linker variant III. Although these 3 compounds had reduced potency compared to NEU-617, they all had improved LogP, LLE and MPO scores. Cross-screening these analogs against other protozoan parasites uncovered IV with potent activity towards T. brucei, T. cruzi and L. major, while four others compounds showed activity towards P. falciparum D6. This reinforces the effectiveness of lead repurposing for the discovery of new protozoan disease therapeutics. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).COA of Formula: C8H10BrN3O

The Article related to anilinoquinazoline trypanosome inhibitor antimalarial malaria trypanosomiasis trypanosomicide, human african trypanosomiasis, leishmania major, neglected tropical disease, plasmodium falciparum, target class repurposing, trypanosoma brucei, trypanosoma cruzi and other aspects.COA of Formula: C8H10BrN3O

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 1, 2020, Semenov, Vyacheslav E.; Zueva, Irina V.; Lushchekina, Sofya V.; Lenina, Oksana A.; Gubaidullina, Lilya M.; Saifina, Lilya F.; Shulaeva, Marina M.; Kayumova, Ramilya M.; Saifina, Alina F.; Gubaidullin, Aidar T.; Kondrashova, Svetlana A.; Latypov, Shamil K.; Masson, Patrick; Petrov, Konstantin A. published an article.Safety of 6-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was 6-Methyluracil derivatives as peripheral site ligand-hydroxamic acid conjugates: Reactivation for paraoxon-inhibited acetylcholinesterase. And the article contained the following:

New uncharged conjugates of 6-methyluracil derivatives with imidazole-2-aldoxime I (n = 1, 2, 3, 4) and 1,2,4-triazole-3-hydroxamic acid units II (n = 2, 3, 4) were synthesized and studied as reactivators of organophosphate-inhibited cholinesterase. Using paraoxon (POX) as a model organophosphate, it was shown that 6-methyluracil derivatives linked with hydroxamic acid are able to reactivate POX-inhibited human acetylcholinesterase (AChE) in vitro. The reactivating efficacy of one compound II (n = 3) is lower than that of pyridinium-2-aldoxime (2-PAM). Meanwhile, unlike 2-PAM, in vivo study showed that the lead compound II (n = 3) is able: (1) to reactivate POX-inhibited AChE in the brain; (2) to decrease death of neurons and, (3) to prevent memory impairment in rat model of POX-induced neurodegeneration. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Safety of 6-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to methyluracil imidazole aldoxime triazole hydroxamic acid preparation mol docking, reactivator paraoxon acetylcholinesterase butyrylcholinesterase inhibitor, 3,6-dimethyluracil, acetylcholinesterase, hydroxamic acids, molecular modeling, paraoxon, reactivator and other aspects.Safety of 6-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Hrabina, Ondrej; Brabec, Viktor; Novakova, Olga published an article in 2019, the title of the article was Translesion DNA synthesis across lesions induced by oxidative products of pyrimidines: an insight into the mechanism by microscale thermophoresis.Quality Control of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione And the article contains the following content:

Oxidative stress in cells can lead to the accumulation of reactive oxygen species and oxidation of DNA precursors. Oxidized nucleotides such as 2′-deoxyribo-5-hydroxyuridin (HdU) and 2′-deoxyribo-5-hydroxymethyluridin (HMdU) can be inserted into DNA during replication and repair. HdU and HMdU have attracted particular interest because they have different effects on damaged-DNA processing enzymes that control the downstream effects of the lesions. Herein, we studied the chem. simulated translesion DNA synthesis (TLS) across the lesions formed by HdU or HMdU using microscale thermophoresis (MST). The thermodn. changes associated with replication across HdU or HMdU show that the HdU paired with the mismatched deoxyribonucleoside triphosphates disturbs DNA duplexes considerably less than thymidine (dT) or HMdU. Moreover, we also demonstrate that TLS by DNA polymerases across the lesion derived from HdU was markedly less extensive and potentially more mutagenic than that across the lesion formed by HMdU. The equilibrium thermodn. data obtained by MST can explain the influence of the thermodn. alterations on the ability of DNA polymerases to bypass lesions induced by oxidative products of pyrimidines. The results also highlighted the usefulness of MST in evaluating the impact of oxidative products of pyrimidines on the processing of these lesions by damaged DNA processing enzymes. The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Quality Control of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

The Article related to translesion dna synthesis deoxyribo hydroxyuridine hydroxymethyluridine polymerase oxidative stress, 2’-deoxyribo-5-hydroxymethyl- uridin, 2’-deoxyribo-5-hydroxyuridin, dna polymerases, microscale thermophoresis, oxidized nucleotides, translesion dna synthesis and other aspects.Quality Control of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Fu, Suhong; Xiang, Wei; Chen, Jinying; Ma, Liang; Chen, Lijuan published an article in 2017, the title of the article was Synthesis and biological evaluation of 1, 2, 4-oxadiazole derivatives as novel GPR119 agonists.Application of 596114-50-0 And the article contains the following content:

Aryloxymethyl piperidinyl 1,2,4-oxadiazoles I [R = Boc, 5-R2-2-pyrimidinyl; R1 = 5-formyl-2-furanyl, 5-formyl-2-thienyl, 5-acetyl-2-thienyl, 4-MeOC6H4, 4-MeSO2C6H4, 1-cyclopropyl-3-pyrazolyl, 1-methyl-3-pyrazolyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-chloro-4-pyridinyl, 6-methoxy-3-pyridinyl, 6-fluoro-3-pyridinyl, 6-methyl-3-pyridinyl, 2-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 5-oxazolyl, 4-(ethoxycarbonyl)-5-methyl-2-thiazolyl, 4-(ethoxycarbonyl)-2-thiazolyl, 2-ethyl-1,2,4-oxadiazol-5-yl; R2 = Et, i-Pr, EtO] were prepared as potential GPR119 agonists; agonism of GPR119 in human cells expressing GPR119, comparison to the pos. control GSK1292263, and their calculated lipophilicities were determined The prepared compounds showed acceptable agonistic effects at GPR119; I (R = Boc; R1 = 5-pyrimidinyl) was the most active GPR119 agonist tested with an EC50 value of 20.6 nM, comparable to that of the pos. control. The structure-activity relationship of the prepared 1,2,4-oxadiazole derivatives for GPR119 agonism was determined The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Application of 596114-50-0

The Article related to butoxycarbonylpiperidinyl pyrimidinylpiperidinyl aryloxymethyl oxadiazole preparation gpr119 agonism lipophilicity, structure butoxycarbonylpiperidinyl pyrimidinylpiperidinyl aryloxymethyl oxadiazole gpr119 agonism, gpcr, gpr119, sar study, agonistic activity, camp and other aspects.Application of 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 5, 2015, Blinn, James Robert; Flick, Andrew Christopher; Wennerstaal, Goeran Mattias; Jones, Peter; Kaila, Neelu; Kiefer, James Richard, Jr.; Kurumbail, Ravi G.; Mente, Scot Richard; Meyers, Marvin Jay; Schnute, Mark Edward; Thorarensen, Atli; Xing, Li; Zamaratski, Edouard; Zapf, Christoph Wolfgang published a patent.Safety of 2-Chloro-5-isopropylpyrimidine The title of the patent was Preparation of N-heteroaryl amides as RORC2 inhibitors. And the patent contained the following:

The present invention provides compounds I-VII [Y = H, halo, CN, etc.; R1 = H, alkyl, hydroxyalkyl, haloalkyl; X = NHC(O)R2, NHC(O)NHR2, NHSO2R2, etc.; R2 = alkyl, cycloalkyl, aryl, etc.; W = N-substituted 4-piperidinyl, 3-piperidinyl, 3-pyrrolidinyl, 3-azetidinyl], pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds I-VII and pharmaceutical compositions Ninety-five compounds I-VII were prepared E.g., a multi-step synthesis of VIII, starting from 5-nitroindole and tert-Bu 4-oxopiperidine-1-carboxylate, was described. Exemplified compounds I were evaluated for RORC2 activity (data given). The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Safety of 2-Chloro-5-isopropylpyrimidine

The Article related to heteroaryl amide preparation rorc2 inhibitor immune inflammatory disorder treatment, antiinflammatory immunomodulator antiarthritic antirheumatic heteroaryl amide preparation interleukin17 decrease, sulfonamide urea amide heteroaryl indolyl pyrrolopyridinyl preparation rorc2 inhibitor and other aspects.Safety of 2-Chloro-5-isopropylpyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 15, 2015, Li, Wei; Liu, Yucan; Duan, Jinming; van Leeuwen, John; Saint, Christopher P. published an article.Computed Properties of 626-48-2 The title of the article was UV and UV/H2O2 treatment of diazinon and its influence on disinfection byproduct formation following chlorination. And the article contained the following:

Incomplete oxidation of organic micro-pollutants may result in diverse, intermittent oxidation byproducts, significantly affecting disinfection byproduct (DBP) formation from the original solutions following chlorination. This work assessed DBP formation from diazinon in solution due to the formation of intermittent oxidation byproducts by UV and UV/H2O2 pre-oxidation Monochloroacetic acid (MCAA), dichloroacetic acid (DCAA), trichloroacetic acid (TCAA), chloroform (TCM), dichloroacetonitrile (DCAN), and 1,1,1-trichloroacetone (1,1,1-TCP) were detected for chlorinated diazinon solutions which were treated by UV and UV/H2O2 oxidation DBP formation significantly increased in diazinon solutions treated by UV irradiation Solution pH and H2O2 dose also had distinct effects on DBP formation, depending on the individual DBP species. Speciation and mol. structures of oxidation byproducts were analyzed by mass spectrometry and tandem mass spectrometry. Four main UV oxidation byproducts (2-isopropyl-6-methyl-4-pyrimidinol [IMP], O-analog diazinon [diazoxon], di-Et thiophosphate [DETP], di-Et phosphate [DEP]) were examined individually to identify their relative contribution to DBP formation. Increased total DBP formation of treated diazinon solutions was mainly attributable to its oxidation product, IMP, and its secondary oxidation products; the other 2 fragments, DETP and DEP, had little effect. Its oxidation fragment, diazoxon, intensified MCAA, DCAA, and TCAA formation under UV/H2O2 pre-oxidation conditions. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Computed Properties of 626-48-2

The Article related to water purification chlorination pre oxidation disinfection, hydrogen peroxide uv irradiation pre oxidation water purification, disinfection byproduct formation diazinon containing water chlorination oxidation disinfection, intermittent oxidation product effect disinfection byproduct formation and other aspects.Computed Properties of 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On May 20, 1999, Smaill, Jeff B.; Palmer, Brian D.; Rewcastle, Gordon W.; Denny, William A.; McNamara, Dennis J.; Dobrusin, Ellen M.; Bridges, Alexander J.; Zhou, Hairong; Showalter, H. D. Hollis; Winters, R. Thomas; Leopold, Wilbur R.; Fry, David W.; Nelson, James M.; Slintak, Veronika; Elliot, William L.; Roberts, Billy J.; Vincent, Patrick W.; Patmore, Sandra J. published an article.Name: 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine The title of the article was Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. And the article contained the following:

A series of 6- and 7-acrylamide derivatives of the 4-(phenylamino)quinazoline and -pyridopyrimidine classes of epidermal growth factor receptor (EGFR) inhibitors, I (R = Br, Cl, Me, X = CH, N), II (R = 3-Br, 3-Cl, 3-Me, 3-CF3, 3-Br-4-F, 3-Cl-4-F, 4-OPh, 4-OCH2Ph), III (R = 3-Br, 3-Br-4-F, 3-Cl-4-F), and IV, were prepared from the corresponding amino compounds by reaction with either acryloyl chloride/base or acrylic acid/1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. All of the 6-acrylamides, but only the parent quinazoline 7-acrylamide, were irreversible inhibitors of the isolated enzyme, confirming that the former are better-positioned, when bound to the enzyme, to react with the critical cysteine-773. Quinazoline, pyrido[3,4-d]pyrimidine, and pyrido[3,2-d]pyrimidine 6-acrylamides were all irreversible inhibitors and showed similar high potencies in the enzyme assay (likely due to titration of the available enzyme). However, the pyrido[3,2-d]pyrimidine analogs were 2-6-fold less potent than the others in a cellular autophosphorylation assay for EGFR in A431 cells. The quinazolines were generally less potent overall toward inhibition of heregulin-stimulated autophosphorylation of erbB2 (in MDA-MB-453-cells), whereas the pyridopyrimidines were equipotent. Selected compounds were evaluated in A431 epidermoid and H125 non-small-cell lung cancer human tumor xenografts. The compounds showed better activity when given orally than i.p. All showed significant tumor growth inhibition (stasis) over a dose range. The poor aqueous solubility of the compounds was a drawback, requiring formulation as fine particulate emulsions. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Name: 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine

The Article related to phenylaminoquinazoline acrylamide preparation egfr inhibitor, phenylaminopyridopyrimidine acrylamide preparation egfr inhibitor, epidermal growth factor receptor inhibitor acrylamide, antitumor quinazoline pyridopyrimidine acrylamide, acrylamide quinazoline pyridopyrimidine egfr inhibitor antitumor and other aspects.Name: 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 20, 2011, Barba, Oscar; Gattrell, William; Smyth, Donald; Swain, Simon published a patent.Recommanded Product: 596114-50-0 The title of the patent was Preparation of 3-substituted 5-(pyrrolidine-1-carbonyl)pyrrolidine and its derivatives for use in the treatment of metabolic disorders. And the patent contained the following:

The title compounds I [p, q = 1-2; Z = NC(O)OR4, NC(O)NR4R5, N-heteroaryl, etc.; Y = CH2, CF2, CHF, O, NR1, C(O) or B (wherein B = 5-membered heteroaryl containing one or more heteroatoms selected from N, O and S); when Y = CH2, CF2, CHF, O, NR1 or C(O), X = (un)branched alkylene; or when Y = O or NR1, X may also be -ACHR2- (wherein A = 5-membered heteroaryl containing one or more heteroatoms selected from N, O and S); and when Y = B, X = OCHR3; Ar = (un)substituted para-substituted 6-membered heteroaryl containing one or two N atoms; R1-R3 = H, alkyl; R4 = aryl, heteroaryl, alkyl,(un)substituted cycloalkyl; R5 = H or alkyl; V = II (T = CH2, or, when m = 1, T may also be S; when T = CH2, R6 = F or CN, and when T = S, R6 = CN; R7 = H, alkyl; m = 0-1; s = 0-2); n = 0-1] which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes, were prepared For example, Pd-catalyzed coupling 2-bromo-5-{3-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]propoxy}pyridine with tert-Bu (2S,4S)-4-amino-2-(pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylate (preparations given) followed by Boc-deprotection afforded (2S,4S)-III. Compounds I produced a concentration-dependent increase in intracellular cAMP level and generally had an EC50 of <10 μM when tested in GPR119 cAMP assay. All exemplified compounds I showed activity in DPP-IV assay having an IC50 of <20 μM. Pharmaceutical composition comprising compound I is disclosed. The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Recommanded Product: 596114-50-0

The Article related to pyrrolidinecarbonylpyrrolidine preparation glucose dependent insulinotropic polypeptide receptor gpr119 agonist, metabolic disorder type ii diabetes treatment pyrrolidinecarbonylpyrrolidine preparation, antidiabetic pyrrolidinecarbonylpyrrolidine preparation gpr119 agonist dipeptidyl peptidase dppiv modulator and other aspects.Recommanded Product: 596114-50-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia